Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum YM BioSciences Inc YMI

Bullboard (NYSEAM:YMI)

View:
Post by chuck8on Nov 23, 2009 7:26pm

news

There is a news release on the website and ties in to what was stated in the recent audio presentation (also on the website) so things are starting to look up IMHO.
Comment by greatemailslobon Nov 22, 2009 10:15am

RE: STOCK PRICE

once they get a commercial liscense and a JV partner its a moon shota good puntin and out once froma buck to 220back in
Post by cacfaon Nov 20, 2009 4:26pm

STOCK PRICE

I listened in to the annual meeting conference call yesterday. For those who did not listen in, I suggest doing so. Everything seems aligned for a huge run up in stock price in the upcoming year ...more  
Post by greatemailslobon Nov 18, 2009 1:01pm

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN AD

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING8 minutes ago - ACQUIREMEDIAnullMISSISSAUGA, ON, Nov. 18 /PRNewswire ...more  
Comment by ftt998on Nov 12, 2009 5:47pm

RE: RE: New data from YM’s nimotuzumab

If link not working, you should just have to cut and paste below into the address window of your browser (don't add anything to the end like .com or .ca)https://biotuesday.ca/2009/10/30/new-data ...more  
Comment by chuck8on Nov 12, 2009 4:50pm

RE: New data from YM’s nimotuzumab

seems like the link is incorrect...can you repost?
Post by ftt998on Nov 12, 2009 1:00pm

New data from YM’s nimotuzumab

https://biotuesday.ca/2009/10/30/new-data-from-ym’s-nimotuzumab/
Post by ftt998on Nov 12, 2009 12:57pm

YM will have much to say in 2010

https://biotuesday.ca/2009/10/08/ym-will-have-much-to-say-in-2010/
Post by insiderinfocanon Nov 08, 2009 6:43pm

Merriman Initiates Coverage Buy Target 5.50-6.50

Merriman Curhan Ford Initiates Coverage on YM BioSciences (YMI) with a Buy; Intriguing Opportunity November 5, 2009 7:51 AM EST Merriman Curhan Ford initiates coverage on YM BioSciences, Inc. (NYSE ...more  
Comment by greatemailslobon Nov 05, 2009 12:33pm

RE: RE: looking to rebuy under a buck

noyoucantpickastocki was here long before you were...made a great pass bought at a buck sold at 220ish for 30000waiting for you to sell your 100 sharesgreat report from Griffin 25 pagesas a ...more  
Post by chuck8on Nov 02, 2009 3:54pm

Good news on website nr

A pretty positive nr on the website today leads me to confirm my belief that YM has lots of upside potential. That 12 month target of $5 may not do justice to what YM has to offer.
Comment by Yeswecanon Oct 29, 2009 10:11pm

RE: looking to rebuy under a buck

slob...you are way too stunned to ever really prosper imo. Calling everyone ladies is inappropriate and you won't be buying this for under a buck any time soon.  Watch the real investors with ...more  
Post by insiderinfocanon Oct 29, 2009 7:13pm

After hours up 12% vol 264023 AMEX

YM BioSciences Inc. AMEX: YMI YM BioSciences Inc. After Hours YMI /quotes/comstock/14*!ymi/quotes/nls/ymi  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities